Purple Biotech Ltd.
As of Oct 22, 2026, Purple Biotech is in Stage 4, the downtrend phase, now in its first week (since Oct 20, 2026). It closed at $1.05, 90.1% below its 52-week high and below its 200-day average, which is falling.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is PPBT early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
PPBT among Biotechnology483rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …483 | PPBT | Stage 4 · wk 1 | 10 | −29.3% |
Purple Biotech: quick answers
What stage is Purple Biotech in?
As of Oct 22, 2026, Purple Biotech (PPBT) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 20, 2026 and is in its first week there. What the four stages mean
Is Purple Biotech in an uptrend?
No. Purple Biotech is in a Stage 4 downtrend. It trades 67.1% below its 200-day average, which is falling.
How far is Purple Biotech from its 52-week high?
Purple Biotech closed at $1.05 on Oct 22, 2026, 90.1% below its 52-week high of $10.60. Its 52-week low is $1.05.
How has Purple Biotech performed over the past year?
As of Oct 22, 2026, Purple Biotech is down 81.8% over the past year and down 84.1% so far in 2026.
Which sector and industry is Purple Biotech in?
Purple Biotech is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.